Search

Your search keyword '"Reichlin, Tobias"' showing total 1,480 results
Start Over Author "Reichlin, Tobias"
1,480 results on '"Reichlin, Tobias"'

101. LB-456091-3 EUROPEAN REAL WORLD OUTCOMES WITH PULSED FIELD ABLATION IN PATIENTS WITH SYMPTOMATIC ATRIAL FIBRILLATION - LESSONS FROM THE MULTICENTER EU-PORIA REGISTRY

Author

Schmidt, Boris, primary, Bordignon, Stefano, additional, Neven, Kars, additional, Reichlin, Tobias, additional, Blaauw, Yuri, additional, Hansen, Jim, additional, Adelino, Raquel, additional, Ouss, Alexandre, additional, Füting, Anna, additional, Roten, Laurent, additional, Mulder, Bart A., additional, Ruwald, Martin H., additional, Menè, Roberto, additional, Van Der Voort, Pepijn H., additional, Reinsch, Nico, additional, Kueffer, Thomas, additional, Boveda, Serge, additional, and Chun, Julian K., additional

Published
2023
Full Text
View/download PDF

102. Eliminating transseptal sheath exchange for pulsed field ablation procedures using a direct over-the-needle transseptal access with the Faradrive sheath

Author

Kueffer, Thomas, Madaffari, Antonio, Thalmann, Gregor, Mühl, Aline, Galuszka, Oskar, Baldinger, Samuel, Seiler, Jens, Tanner, Hildegard, Kobza, Richard, Roten, Laurent, Berte, Benjamin, and Reichlin, Tobias

Subjects
Physiology (medical), 610 Medicine & health, 610 Medizin und Gesundheit, Cardiology and Cardiovascular Medicine
Abstract

Aims Pulsed field ablation (PFA) for pulmonary vein isolation (PVI) combines the benefits of high procedural efficacy and safety. Transseptal puncture (TSP) to obtain left atrial (LA) access during PVI remains an important source of complications during LA procedures. For PFA procedures, TSP is generally performed using a standard transseptal sheath that is then exchanged over the wire for a dedicated PFA sheath, which might be a potential source for air embolism. We aimed to prospectively evaluate the feasibility and safety of a simplified workflow using the PFA sheath (Faradrive, Boston Scientific) directly for TSP. Methods and Results We prospectively enrolled 100 patients undergoing PVI using PFA at two centres. TSP was performed using the PFA sheath and a standard 98 cm transseptal needle under fluoroscopic guidance. TSP via the PFA sheath was successfully performed in all patients and no complications occurred. The median time from the first groin puncture to the completed LA access was 12 min (IQR 8–16 min). Conclusion An over-the-needle TSP directly with the PFA sheath proved feasible and safe in our study. This simplified workflow has the potential to reduce the risk of air embolism, to shorten procedure time, and to reduce cost.

Published
2023

103. Diagnostic value of ST-segment deviations during cardiac exercise stress testing: Systematic comparison of different ECG leads and time-points

Author

Puelacher, Christian, Wagener, Max, Abächerli, Roger, Honegger, Ursina, Lhasam, Nundsin, Schaerli, Nicolas, Prêtre, Gil, Strebel, Ivo, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Rubini Giménez, Maria, Hillinger, Petra, Wildi, Karin, Sabti, Zaid, Badertscher, Patrick, Cupa, Janosch, Kozhuharov, Nikola, du Fay de Lavallaz, Jeanne, Freese, Michael, Roux, Isabelle, Lohrmann, Jens, Leber, Remo, Osswald, Stefan, Wild, Damian, Zellweger, Michael J., Mueller, Christian, and Reichlin, Tobias

Published
2017
Full Text
View/download PDF

104. Diagnostic and prognostic values of the V-index, a novel ECG marker quantifying spatial heterogeneity of ventricular repolarization, in patients with symptoms suggestive of non-ST-elevation myocardial infarction

Author

Abächerli, Roger, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Mächler, Patrick, Sassi, Roberto, Rivolta, Massimo W, Roonizi, Ebadollah Kheirati, Mainardi, Luca T, Kozhuharov, Nikola, Rubini Giménez, Maria, Wildi, Karin, Grimm, Karin, Sabti, Zaid, Hillinger, Petra, Puelacher, Christian, Strebel, Ivo, Cupa, Janosch, Badertscher, Patrick, Roux, Isabelle, Schmid, Ramun, Leber, Remo, Osswald, Stefan, Mueller, Christian, and Reichlin, Tobias

Published
2017
Full Text
View/download PDF

106. Diagnostic and Prognostic Value of Lead aVR During Exercise Testing in Patients Suspected of Having Myocardial Ischemia

Author

Wagener, Max, Abächerli, Roger, Honegger, Ursina, Schaerli, Nicolas, Prêtre, Gil, Twerenbold, Raphael, Puelacher, Christian, Sunier, Germaine, Reddiess, Philipp, Rubini Gimenez, Maria, Wildi, Karin, Boeddinghaus, Jasper, Nestelberger, Thomas, Badertscher, Patrick, Sabti, Zaid, Schmid, Ramun, Leber, Remo, Widmer, Dayana Flores, Shrestha, Samyut, Strebel, Ivo, Wild, Damian, Osswald, Stefan, Zellweger, Michael, Mueller, Christian, and Reichlin, Tobias

Published
2017
Full Text
View/download PDF

108. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study.

Author

Moutzouri, Elisavet, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin, Adam, Luise, Gencer, Baris, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E, Hennings, Elisa, Aeschbacher, Stefanie, Beer, Jürg H, Moschovitis, Giorgio, Seiffge, David, De Marchis, Gian Marco, Coslovsky, Michael, Reichlin, Tobias, Conte, Giulio, Sinnecker, Tim, and Schwenkglenks, Matthias

Subjects
INTRACRANIAL hemorrhage, STATINS (Cardiovascular agents), ATRIAL fibrillation, TRANSIENT ischemic attack, CORONARY disease
Abstract

Background: An increased risk of intracranial hemorrhage (ICH) associated with statins has been reported, but data on the relationship between statin use and cerebral microbleeds (CMBs) in patients with atrial fibrillation (AF), a population at high bleeding and cardiovascular risk, are lacking. Aims: To explore the association between statin use and blood lipid levels with the prevalence and progression of CMBs in patients with AF with a particular focus on anticoagulated patients. Methods: Data of Swiss-AF, a prospective cohort of patients with established AF, were analyzed. Statin use was assessed during baseline and throughout follow-up. Lipid values were measured at baseline. CMBs were assessed using magnetic resonance imagining (MRI) at baseline and at 2 years follow-up. Imaging data were centrally assessed by blinded investigators. Associations of statin use and low-density lipoprotein (LDL) levels with CMB prevalence at baseline or CMB progression (at least one additional or new CMB on follow-up MRI at 2 years compared with baseline) were assessed using logistic regression models; the association with ICH was assessed using flexible parametric survival models. Models were adjusted for hypertension, smoking, body mass index, diabetes, stroke/transient ischemic attack, coronary heart disease, antiplatelet use, anticoagulant use, and education. Results: Of the 1693 patients with CMB data at baseline MRI (mean ± SD age 72.5 ± 8.4 years, 27.6% women, 90.1% on oral anticoagulants), 802 patients (47.4%) were statin users. The multivariable adjusted odds ratio (adjOR) for CMBs prevalence at baseline for statin users was 1.10 (95% CI = 0.83–1.45). AdjOR for 1 unit increase in LDL levels was 0.95 (95% CI = 0.82–1.10). At 2 years, 1188 patients had follow-up MRI. CMBs progression was observed in 44 (8.0%) statin users and 47 (7.4%) non-statin users. Of these patients, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 developed more than 3 CMBs. The multivariable adjOR for statin users was 1.09 (95% CI = 0.66–1.80). There was no association between LDL levels and CMB progression (adjOR 1.02, 95% CI = 0.79–1.32). At follow-up 14 (1.2%) statin users had ICH versus 16 (1.3%) non-users. The age and sex adjusted hazard ratio (adjHR) was 0.75 (95% CI = 0.36–1.55). The results remained robust in sensitivity analyses excluding participants without anticoagulants. Conclusions: In this prospective cohort of patients with AF, a population at increased hemorrhagic risk due to anticoagulation, the use of statins was not associated with an increased risk of CMBs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

109. Longitudinal Changes in Health-Related Quality of Life in Patients With Atrial Fibrillation.

Author

Foster-Witassek, Fabienne, Aebersold, Helena, Aeschbacher, Stefanie, Ammann, Peter, Beer, Jürg H., Blozik, Eva, Bonati, Leo H., Cattaneo, Mattia, Coslovsky, Michael, Felder, Stefan, Moschovitis, Giorgio, Müller, Andreas, Netzer, Seraina, Paladini, Rebecca E., Reichlin, Tobias, Rodondi, Nicolas, Stauber, Annina, Sticherling, Christian, Szucs, Thomas, and Conen, David

Published
2023
Full Text
View/download PDF

110. Arrhythmias and Clinical Outcomes in a Swiss Multicenter Cohort of Patients With Dextro-Transposition of the Great Arteries and Atrial Switch

Author

Nozica, Nikolas, Asatryan, Babken, Aur, Stefania, Clement, Judith Bouchardy, Schwerzmann, Markus, Guan, Fu, Pascale, Patrizio, Gass, Matthias, Duru, Firat, Reichlin, Tobias, Pruvot, Etienne, Wolber, Thomas, and Roten, Laurent

Subjects
610 Medicine & health
Abstract

Background Data on the incidence of arrhythmias, associated cardiac interventions, and outcome in patients with dextro-transposition of the great arteries and atrial switch are scarce. Methods and Results In this multicenter analysis, we included adult patients with dextro-transposition of the great arteries and atrial switch regularly followed up at 3 Swiss tertiary care hospitals. The primary outcome was a composite of left ventricular assist device, heart transplantation, and death. The secondary outcome was occurrence of ventricular tachycardia, ventricular fibrillation, or sudden cardiac death. We identified 207 patients (34% women; median age at last follow-up, 35 years) with dextro-transposition of the great arteries and atrial switch. Arrhythmias occurred in 97 patients (47%) at a median age of 22 years. A pacemaker or an implantable cardioverter-defibrillator was implanted in 39 (19%) and 13 (6%) patients, respectively, and 33 (16%) patients underwent a total of 51 ablation procedures to target 60 intra-atrial re-entry tachycardias, 4 atrioventricular nodal re-entry tachycardias, and 1 atrial fibrillation. The primary outcome occurred in 21 patients (10%), and the secondary outcome occurred in 18 patients (9%); both were more common in patients with concomitant ventricular septum defect than in those without (hazard ratio [HR], 3.06 [95% CI, 1.29-7.27], P=0.011; and HR, 3.62 [95% CI, 1.43-9.18], P=0.007, respectively). Conclusions In patients with dextro-transposition of the great arteries and atrial switch reaching adulthood, arrhythmias occur in almost half of patients, and associated rhythm interventions are frequent. One-tenth of those patients do not survive until the age of 35 years free from left ventricular assist device or heart transplantation, and the outcome is worse in patients with concomitant ventricular septum defect.

Published
2023

111. Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality

Author

Badertscher, Patrick, Strebel, Ivo, Honegger, Ursina, Schaerli, Nicolas, Mueller, Deborah, Puelacher, Christian, Wagener, Max, Abächerli, Roger, Walter, Joan, Sabti, Zaid, Sazgary, Lorraine, Marbot, Stella, du Fay de Lavallaz, Jeanne, Twerenbold, Raphael, Boeddinghaus, Jasper, Nestelberger, Thomas, Kozhuharov, Nikola, Breidthardt, Tobias, Shrestha, Samyut, Flores, Dayana, Schumacher, Carmela, Wild, Damian, Osswald, Stefan, Zellweger, Michael J., Mueller, Christian, and Reichlin, Tobias

Published
2018
Full Text
View/download PDF

114. Acute and long‐term outcomes of quadripolar IS‐4 versus bipolar IS‐1 left ventricular leads in cardiac resynchronization therapy: A retrospective registry study

Author

Maurhofer, Jens, primary, Asatryan, Babken, additional, Haeberlin, Andreas, additional, Noti, Fabian, additional, Roten, Laurent, additional, Seiler, Jens, additional, Baldinger, Samuel H, additional, Franzeck, Florian, additional, Lam, Anna, additional, Kueffer, Thomas, additional, Reichlin, Tobias, additional, Tanner, Hildegard, additional, and Servatius, Helge, additional

Published
2023
Full Text
View/download PDF

116. European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author

Aktaa, S, Tzeis, S, Gale, C, Ackerman, M, Arbelo, E, Behr, E, Crotti, L, D'Avila, A, de Chillou, C, Deneke, T, Figueiredo, M, Friede, T, Leclercq, C, Merino, J, Semsarian, C, Verstrael, A, Zeppenfeld, K, Tfelt-Hansen, J, Reichlin, T, Aktaa, Suleman, Tzeis, Stylianos, Gale, Chris P, Ackerman, Michael J, Arbelo, Elena, Behr, Elijah R, Crotti, Lia, d'Avila, Andre, de Chillou, Christian, Deneke, Thomas, Figueiredo, Márcio, Friede, Tim, Leclercq, Christophe, Merino, Jose L, Semsarian, Chris, Verstrael, Axel, Zeppenfeld, Katja, Tfelt-Hansen, Jacob, Reichlin, Tobias, Aktaa, S, Tzeis, S, Gale, C, Ackerman, M, Arbelo, E, Behr, E, Crotti, L, D'Avila, A, de Chillou, C, Deneke, T, Figueiredo, M, Friede, T, Leclercq, C, Merino, J, Semsarian, C, Verstrael, A, Zeppenfeld, K, Tfelt-Hansen, J, Reichlin, T, Aktaa, Suleman, Tzeis, Stylianos, Gale, Chris P, Ackerman, Michael J, Arbelo, Elena, Behr, Elijah R, Crotti, Lia, d'Avila, Andre, de Chillou, Christian, Deneke, Thomas, Figueiredo, Márcio, Friede, Tim, Leclercq, Christophe, Merino, Jose L, Semsarian, Chris, Verstrael, Axel, Zeppenfeld, Katja, Tfelt-Hansen, Jacob, and Reichlin, Tobias

Abstract

To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD.

Published
2023

117. European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author

Aktaa, Suleman, Tzeis, Stylianos, Gale, Chris P., Ackerman, Michael J., Arbelo, Elena, Behr, Elijah R., Crotti, Lia, d'Avila, Andre, de Chillou, Christian, Deneke, Thomas, Figueiredo, Márcio, Friede, Tim, Leclercq, Christophe, Merino, Jose L., Semsarian, Chris, Verstrael, Axel, Zeppenfeld, Katja, Tfelt-Hansen, Jacob, Reichlin, Tobias, Aktaa, Suleman, Tzeis, Stylianos, Gale, Chris P., Ackerman, Michael J., Arbelo, Elena, Behr, Elijah R., Crotti, Lia, d'Avila, Andre, de Chillou, Christian, Deneke, Thomas, Figueiredo, Márcio, Friede, Tim, Leclercq, Christophe, Merino, Jose L., Semsarian, Chris, Verstrael, Axel, Zeppenfeld, Katja, Tfelt-Hansen, Jacob, and Reichlin, Tobias

Abstract

To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD.

Published
2023

118. Recurrences of ventricular tachycardia after stereotactic arrhythmia radioablation arise outside the treated volume: analysis of the Swiss cohort

Author

MS Radiotherapie, Brain, Cancer, Circulatory Health, Herrera Siklody, Claudia, Schiappacasse, Luis, Jumeau, Raphaël, Reichlin, Tobias, Saguner, Ardan M, Andratschke, Nicolaus, Elicin, Olgun, Schreiner, Frederic, Kovacs, Boldizsar, Mayinger, Michael, Huber, Adrian, Verhoeff, Joost J C, Pascale, Patrizio, Solana Muñoz, Jorge, Luca, Adrian, Domenichini, Giulia, Moeckli, Raphael, Bourhis, Jean, Ozsahin, Esat M, Pruvot, Etienne, MS Radiotherapie, Brain, Cancer, Circulatory Health, Herrera Siklody, Claudia, Schiappacasse, Luis, Jumeau, Raphaël, Reichlin, Tobias, Saguner, Ardan M, Andratschke, Nicolaus, Elicin, Olgun, Schreiner, Frederic, Kovacs, Boldizsar, Mayinger, Michael, Huber, Adrian, Verhoeff, Joost J C, Pascale, Patrizio, Solana Muñoz, Jorge, Luca, Adrian, Domenichini, Giulia, Moeckli, Raphael, Bourhis, Jean, Ozsahin, Esat M, and Pruvot, Etienne

Published
2023

119. STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

Author

Computational Imaging, Cancer, Funding & Support, Team Medisch, Circulatory Health, Experimentele klinische fysica, MS Radiotherapie, Grehn, Melanie, Mandija, Stefano, Miszczyk, Marcin, Krug, David, Tomasik, Bartłomiej, Stickney, Kristine E, Alcantara, Pino, Alongi, Filippo, Anselmino, Matteo, Aranda, Ricardo Salgado, Balgobind, Brian V, Boda-Heggemann, Judit, Boldt, Leif-Hendrik, Bottoni, Nicola, Cvek, Jakub, Elicin, Olgun, De Ferrari, Gaetano Maria, Hassink, Rutger J, Hazelaar, Colien, Hindricks, Gerhard, Hurkmans, Coen, Iotti, Cinzia, Jadczyk, Tomasz, Jiravsky, Otakar, Jumeau, Raphaël, Buus Kristiansen, Steen, Levis, Mario, López, Manuel Algara, Martí-Almor, Julio, Mehrhof, Felix, Møller, Ditte Sloth, Molon, Giulio, Ouss, Alexandre, Peichl, Petr, Plasek, Jiri, Postema, Pieter G, Quesada, Aurelio, Reichlin, Tobias, Rordorf, Roberto, Rudic, Boris, Saguner, Ardan M, Ter Bekke, Rachel M A, Torrecilla, José López, Troost, Esther G C, Vitolo, Viviana, Andratschke, Nicolaus, Zeppenfeld, Katja, Blamek, Slawomir, Fast, Martin, de Panfilis, Ludovica, Blanck, Oliver, Pruvot, Etienne, Verhoeff, Joost J C, Computational Imaging, Cancer, Funding & Support, Team Medisch, Circulatory Health, Experimentele klinische fysica, MS Radiotherapie, Grehn, Melanie, Mandija, Stefano, Miszczyk, Marcin, Krug, David, Tomasik, Bartłomiej, Stickney, Kristine E, Alcantara, Pino, Alongi, Filippo, Anselmino, Matteo, Aranda, Ricardo Salgado, Balgobind, Brian V, Boda-Heggemann, Judit, Boldt, Leif-Hendrik, Bottoni, Nicola, Cvek, Jakub, Elicin, Olgun, De Ferrari, Gaetano Maria, Hassink, Rutger J, Hazelaar, Colien, Hindricks, Gerhard, Hurkmans, Coen, Iotti, Cinzia, Jadczyk, Tomasz, Jiravsky, Otakar, Jumeau, Raphaël, Buus Kristiansen, Steen, Levis, Mario, López, Manuel Algara, Martí-Almor, Julio, Mehrhof, Felix, Møller, Ditte Sloth, Molon, Giulio, Ouss, Alexandre, Peichl, Petr, Plasek, Jiri, Postema, Pieter G, Quesada, Aurelio, Reichlin, Tobias, Rordorf, Roberto, Rudic, Boris, Saguner, Ardan M, Ter Bekke, Rachel M A, Torrecilla, José López, Troost, Esther G C, Vitolo, Viviana, Andratschke, Nicolaus, Zeppenfeld, Katja, Blamek, Slawomir, Fast, Martin, de Panfilis, Ludovica, Blanck, Oliver, Pruvot, Etienne, and Verhoeff, Joost J C

Published
2023

120. Mid-term changes in cognitive functions in patients with atrial fibrillation: a longitudinal analysis of the Swiss-AF cohort

Author

Wueest, Alexandra S, Zuber, Priska, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rommers, Nikki; https://orcid.org/0000-0003-0311-5009, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Beer, Juerg H, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Conen, David; https://orcid.org/0000-0002-2459-5251, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Mueller, Andreas S, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kuhne, Michael, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Monsch, Andreas U, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Wueest, Alexandra S, Zuber, Priska, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rommers, Nikki; https://orcid.org/0000-0003-0311-5009, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Beer, Juerg H, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Conen, David; https://orcid.org/0000-0002-2459-5251, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Mueller, Andreas S, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kuhne, Michael, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Monsch, Andreas U, and Bonati, Leo H; https://orcid.org/0000-0003-1163-8133

Abstract

Background: Longitudinal association studies of atrial fibrillation (AF) and cognitive functions have shown an unclear role of AF-type and often differ in methodological aspects. We therefore aim to investigate longitudinal changes in cognitive functions in association with AF-type (non-paroxysmal vs. paroxysmal) and comorbidities in the Swiss-AF cohort. Methods: Seven cognitive measures were administered up to five times between 2014 and 2022. Age-education standardized scores were calculated and association between longitudinal change in scores and baseline AF-type investigated using linear mixed-effects models. Associations between AF-type and time to cognitive drop, an observed score of at least one standard deviation below individual's age-education standardized cognitive scores at baseline, were studied using Cox proportional hazard models of each cognitive test, censoring patients at their last measurement. Models were adjusted for baseline covariates.Results2,415 AF patients (mean age 73.2 years; 1,080 paroxysmal, 1,335 non-paroxysmal AF) participated in this Swiss multicenter prospective cohort study. Mean cognitive scores increased longitudinally (median follow-up 3.97 years). Non-paroxysmal AF patients showed smaller longitudinal increases in Digit Symbol Substitution Test (DSST), Cognitive Construct Score (CoCo)and Trail Making Test part B (TMT-B) scores vs. paroxysmal AF patients. Diabetes, history of stroke/TIA and depression were associated with worse performance on all cognitive tests. No differences in time to cognitive drop were observed between AF-types in any cognitive test. Conclusion: This study indicated preserved cognitive functioning in AF patients, best explained by practice effects. Smaller practice effects were found in non-paroxysmal AF patients in the DSST, TMT-B and the CoCo and could indicate a marker of subtle cognitive decline. As diabetes, history of stroke/TIA and depression—but not AF-type—were associated with cognitive drop, mor

Published
2023

121. Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation

Author

Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Blum, Steffen; https://orcid.org/0000-0002-0325-8993, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Knecht, Sven; https://orcid.org/0000-0001-7122-021X, Eken, Ceylan, Lischer, Mirko; https://orcid.org/0000-0001-7088-2801, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Ammann, Peter, Conte, Giulio; https://orcid.org/0000-0003-2248-3456, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Blum, Manuel R, Bossard, Matthias; https://orcid.org/0000-0002-8290-661X, Kastner, Peter; https://orcid.org/0000-0001-8744-7152, Ziegler, André; https://orcid.org/0000-0002-9838-8087, Müller, Christian; https://orcid.org/0000-0002-1120-6405, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Pfister, Otmar; https://orcid.org/0000-0002-6155-5494, Zuern, Christine S; https://orcid.org/0000-0001-6625-284X, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Blum, Steffen; https://orcid.org/0000-0002-0325-8993, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Knecht, Sven; https://orcid.org/0000-0001-7122-021X, Eken, Ceylan, Lischer, Mirko; https://orcid.org/0000-0001-7088-2801, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Ammann, Peter, Conte, Giulio; https://orcid.org/0000-0003-2248-3456, De Perna, Maria Luisa; https://orcid.org/0000-0003-1171-7640, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Blum, Manuel R, Bossard, Matthias; https://orcid.org/0000-0002-8290-661X, Kastner, Peter; https://orcid.org/0000-0001-8744-7152, Ziegler, André; https://orcid.org/0000-0002-9838-8087, Müller, Christian; https://orcid.org/0000-0002-1120-6405, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Pfister, Otmar; https://orcid.org/0000-0002-6155-5494, Zuern, Christine S; https://orcid.org/0000-0001-6625-284X, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, and Osswald, Stefan; https://orcid.org/0000-0002-9240-6731

Abstract

Background Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial‐specific biomarker BMP10 (bone morphogenetic protein 10) for death and MACE in patients with AF in comparison with NT‐proBNP (N‐terminal prohormone of B‐type natriuretic peptide). Methods and Results BMP10 and NT‐proBNP were measured in patients with AF enrolled in Swiss‐AF (Swiss Atrial Fibrillation Study), a prospective multicenter cohort study. A total of 2219 patients were included (median follow‐up 4.3 years [interquartile range 3.9, 5.1], mean age 73±9 years, 73% male). In multivariable Cox proportional hazard models, the adjusted hazard ratio (aHR) associated with 1 ng/mL increase of BMP10 was 1.60 (95% CI, 1.37–1.87) for all‐cause death, and 1.54 (95% CI, 1.35–1.76) for MACE. For all‐cause death, the concordance index was 0.783 (95% CI, 0.763–0.809) for BMP10, 0.784 (95% CI, 0.765–0.810) for NT‐proBNP, and 0.789 (95% CI, 0.771–0.815) for both biomarkers combined. For MACE, the concordance index was 0.732 (95% CI, 0.715–0.754) for BMP10, 0.747 (95% CI, 0.731–0.768) for NT‐proBNP, and 0.750 (95% CI, 0.734–0.771) for both biomarkers combined. When grouping patients according to NT‐proBNP categories (<300, 300–900, >900 ng/L), higher aHRs were observed in patients with high BMP10 in the categories of low NT‐proBNP (all‐cause death aHR, 2.28 [95% CI, 1.15–4.52], MACE aHR, 1.88 [95% CI, 1.07–3.28]) and high NT‐proBNP (all‐cause death aHR, 1.61 [95% CI, 1.14–2.26], MACE aHR, 1.38 [95% CI, 1.07–1.80]). Conclusions BMP10 strongly predicted all‐cause death and MACE in patients with AF. BMP10 provided additional prognostic information in low‐ and high‐risk patients according to NT‐proBNP stratification. Registration https://www.clinicaltrials.gov ; Unique identifier: NCT02105844.

Published
2023

122. Transvenous Lead Extraction during Cardiac Implantable Device Upgrade: Results from the Multicenter Swiss Lead Extraction Registry

Author

Haeberlin, Andreas; https://orcid.org/0000-0002-9283-0110, Noti, Fabian; https://orcid.org/0000-0002-2719-5149, Breitenstein, Alexander; https://orcid.org/0000-0002-4440-2947, Auricchio, Angelo, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Klersy, Catherine; https://orcid.org/0000-0003-0314-8548, Curti, Moreno, Pruvot, Etienne; https://orcid.org/0000-0003-1386-9285, Domenichini, Giulia, Schaer, Beat, Kühne, Michael, Gruszczynski, Michal, Burri, Haran, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Grebmer, Christian, Regoli, François D, Haeberlin, Andreas; https://orcid.org/0000-0002-9283-0110, Noti, Fabian; https://orcid.org/0000-0002-2719-5149, Breitenstein, Alexander; https://orcid.org/0000-0002-4440-2947, Auricchio, Angelo, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Klersy, Catherine; https://orcid.org/0000-0003-0314-8548, Curti, Moreno, Pruvot, Etienne; https://orcid.org/0000-0003-1386-9285, Domenichini, Giulia, Schaer, Beat, Kühne, Michael, Gruszczynski, Michal, Burri, Haran, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Grebmer, Christian, and Regoli, François D

Abstract

BACKGROUND: Device patients may require upgrade interventions from simpler to more complex cardiac implantable electronic devices. Prior to upgrading interventions, clinicians need to balance the risks and benefits of transvenous lead extraction (TLE), additional lead implantation or lead abandonment. However, evidence on procedural outcomes of TLE at the time of device upgrade is scarce. METHODS: This is a post hoc analysis of the investigator-initiated multicenter Swiss TLE registry. The objectives were to assess patient and procedural factors influencing TLE outcomes at the time of device upgrades. RESULTS: 941 patients were included, whereof 83 (8.8%) had TLE due to a device upgrade. Rotational mechanical sheaths were more often used in upgraded patients (59% vs. 42.7%, p = 0.015) and total median procedure time was longer in these patients (160 min vs. 105 min, p < 0.001). Clinical success rates of upgraded patients compared to those who received TLE due to other reasons were not different (97.6% vs. 93.0%, p = 0.569). Moreover, multivariable analysis showed that upgrade procedures were not associated with a greater risk for complications (HR 0.48, 95% confidence interval 0.14-1.57, p = 0.224; intraprocedural complication rate of upgraded patients 7.2% vs. 5.5%). Intraprocedural complications of upgraded patients were mostly associated with the implantation and not the extraction procedure (67% vs. 33% of complications). CONCLUSIONS: TLE during device upgrade is effective and does not attribute a disproportionate risk to the upgrade procedure.

Published
2023

123. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study

Author

Moutzouri, Elisavet; https://orcid.org/0000-0002-7713-7553, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin; https://orcid.org/0000-0003-2519-836X, Adam, Luise, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Seiffge, David, De Marchis, Gian Marco; https://orcid.org/0000-0002-0342-9780, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Sinnecker, Tim, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Kastner, Peter, Aujesky, Drahomir; https://orcid.org/0000-0002-3970-2670, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Fischer, Urs; https://orcid.org/0000-0003-0521-4051, Conen, David; https://orcid.org/0000-0002-2459-5251, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Moutzouri, Elisavet; https://orcid.org/0000-0002-7713-7553, Glutz, Matthias, Abolhassani, Nazanin, Feller, Martin; https://orcid.org/0000-0003-2519-836X, Adam, Luise, Gencer, Baris; https://orcid.org/0000-0002-8954-9694, Del Giovane, Cinzia, Bétrisey, Sylvain, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Hennings, Elisa; https://orcid.org/0000-0003-2616-5535, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Seiffge, David, De Marchis, Gian Marco; https://orcid.org/0000-0002-0342-9780, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Conte, Giulio, Sinnecker, Tim, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Kastner, Peter, Aujesky, Drahomir; https://orcid.org/0000-0002-3970-2670, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Fischer, Urs; https://orcid.org/0000-0003-0521-4051, Conen, David; https://orcid.org/0000-0002-2459-5251, and Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896

Abstract

BACKGROUND An increased risk of intracranial hemorrhage (ICH) associated with statins has been reported, but data on the relationship between statin use and cerebral microbleeds (CMBs) in patients with atrial fibrillation (AF), a population at high bleeding and cardiovascular risk, are lacking. AIMS To explore the association between statin use and blood lipid levels with the prevalence and progression of CMBs in patients with AF with a particular focus on anticoagulated patients. METHODS Data of Swiss-AF, a prospective cohort of patients with established AF, were analyzed. Statin use was assessed during baseline and throughout follow-up. Lipid values were measured at baseline. CMBs were assessed using magnetic resonance imagining (MRI) at baseline and at 2 years follow-up. Imaging data were centrally assessed by blinded investigators. Associations of statin use and low-density lipoprotein (LDL) levels with CMB prevalence at baseline or CMB progression (at least one additional or new CMB on follow-up MRI at 2 years compared with baseline) were assessed using logistic regression models; the association with ICH was assessed using flexible parametric survival models. Models were adjusted for hypertension, smoking, body mass index, diabetes, stroke/transient ischemic attack, coronary heart disease, antiplatelet use, anticoagulant use, and education. RESULTS Of the 1693 patients with CMB data at baseline MRI (mean ± SD age 72.5 ± 8.4 years, 27.6% women, 90.1% on oral anticoagulants), 802 patients (47.4%) were statin users. The multivariable adjusted odds ratio (adjOR) for CMBs prevalence at baseline for statin users was 1.10 (95% CI = 0.83-1.45). AdjOR for 1 unit increase in LDL levels was 0.95 (95% CI = 0.82-1.10). At 2 years, 1188 patients had follow-up MRI. CMBs progression was observed in 44 (8.0%) statin users and 47 (7.4%) non-statin users. Of these patients, 64 (70.3%) developed a single new CMB, 14 (15.4%) developed 2 CMBs, and 13 developed more than 3 CMBs. The

Published
2023

124. Longitudinal Changes in Health-Related Quality of Life in Patients With Atrial Fibrillation

Author

Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Ammann, Peter, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0009-0004-6773-4487, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Cattaneo, Mattia, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Müller, Andreas; https://orcid.org/0000-0001-7845-9012, Netzer, Seraina, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Ammann, Peter, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0009-0004-6773-4487, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Cattaneo, Mattia, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Müller, Andreas; https://orcid.org/0000-0001-7845-9012, Netzer, Seraina, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

Background: Optimizing health-related quality of life (HRQoL) is an important aim of atrial fibrillation (AF) treatment. Little is known about patients' long-term HRQoL trajectories and the impact of patient and disease characteristics. The aim of this study was to describe HRQoL trajectories in an observational AF study population and in clusters of patients with similar patient and disease characteristics. Methods and Results: We used 5-year follow-up data from the Swiss-Atrial Fibrillation prospective cohort, which enrolled 2415 patients with prevalent AF from 2014 to 2017. HRQoL data, collected yearly, comprised EuroQoL-5 dimension utilities and EuroQoL visual analog scale scores. Patient clusters with similar characteristics at enrollment were identified using hierarchical clustering. HRQoL trajectories were analyzed descriptively and with inverse probability-weighted regressions. Effects of postbaseline clinical events were additionally assessed using time-shifted event variables. Among 2412 (99.9%) patients with available baseline HRQoL, 3 clusters of patients with AF were identified, which we characterized as follows: "cardiovascular dominated," "isolated symptomatic," and "severely morbid without cardiovascular disease." Utilities and EuroQoL visual analog scale scores remained stable over time for the full population and the clusters; isolated symptomatic patients showed higher levels of HRQoL. Utilities were reduced after occurrences of stroke, hospitalization for heart failure, and bleeding, by -0.12 (95% CI, -0.18 to -0.06), -0.10 (95% CI, -0.13 to -0.08), and -0.06 (95% CI, -0.08 to -0.04), respectively, on a 0 to 1 utility scale. Utility of surviving patients returned to preevent levels 4 years after heart failure hospitalization; 3 years after bleeding; and 1 year after stroke. Conclusions: In patients with prevalent AF, HRQoL was stable over time, irrespective of baseline patient characteristics. Clinical events of hospitalization for heart failure

Published
2023

125. Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls

Author

Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Brüngger, Beat; https://orcid.org/0000-0001-6173-5375, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg-Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0000-0002-0620-6873, Blum, Manuel, Bonati, Leo, Conen, David; https://orcid.org/0000-0002-2459-5251, Conte, Giulio, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Huber, Carola; https://orcid.org/0000-0002-2469-0435, Kuehne, Michael, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Mueller, Andreas, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Brüngger, Beat; https://orcid.org/0000-0001-6173-5375, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg-Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0000-0002-0620-6873, Blum, Manuel, Bonati, Leo, Conen, David; https://orcid.org/0000-0002-2459-5251, Conte, Giulio, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Huber, Carola; https://orcid.org/0000-0002-2469-0435, Kuehne, Michael, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Mueller, Andreas, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

AIMS Atrial fibrillation (AF) costs are expected to be substantial, but cost comparisons with the general population are scarce. Using data from the prospective Swiss-AF cohort study and population-based controls, we estimated the impact of AF on direct healthcare costs from the Swiss statutory health insurance perspective. METHODS Swiss-AF patients, enrolled from 2014 to 2017, had documented, prevalent AF. We analysed 5 years of follow-up, where clinical data, and health insurance claims in 42% of the patients were collected on a yearly basis. Controls from a health insurance claims database were matched for demographics and region. The cost impact of AF was estimated using five different methods: (1) ordinary least square regression (OLS), (2) OLS-based two-part modelling, (3) generalised linear model-based two-part modelling, (4) 1:1 nearest neighbour propensity score matching and (5) a cost adjudication algorithm using Swiss-AF data non-comparatively and considering clinical data. Cost of illness at the Swiss national level was modelled using obtained cost estimates, prevalence from the Global Burden of Disease Project, and Swiss population data. RESULTS The 1024 Swiss-AF patients with available claims data were compared with 16 556 controls without known AF. AF patients accrued CHF5600 (EUR5091) of AF-related direct healthcare costs per year, in addition to non-AF-related healthcare costs of CHF11100 (EUR10 091) per year accrued by AF patients and controls. All five methods yielded comparable results. AF-related costs at the national level were estimated to amount to 1% of Swiss healthcare expenditure. CONCLUSIONS We robustly found direct medical costs of AF patients were 50% higher than those of population-based controls. Such information on the incremental cost burden of AF may support healthcare capacity planning.

Published
2023

126. Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

Author

Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Blum, Manuel R, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Conen, David; https://orcid.org/0000-0002-2459-5251, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Blum, Manuel R, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Conen, David; https://orcid.org/0000-0002-2459-5251, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

OBJECTIVES Randomized controlled trials of pulmonary vein isolation (PVI) for treating atrial fibrillation (AF) have proven the procedure's efficacy. Studies assessing its empirical cost-effectiveness outside randomized trial settings are lacking. We aimed to evaluate the effectiveness and cost-effectiveness of PVI versus medical therapy for AF. METHODS We followed a target trial approach using the Swiss-AF cohort, a prospective observational cohort study that enrolled patients with AF between 2014 and 2017. Resource utilization and cost information were collected through claims data. Quality of life was measured with EQ-5D-3L utilities. We estimated incremental cost-effectiveness ratios (ICERs) from the perspective of the Swiss statutory health insurance system. RESULTS Patients undergoing PVI compared with medical therapy had a 5-year overall survival advantage with a hazard ratio of 0.75 (95% CI 0.46-1.21; P = .69) and a 19.8% SD improvement in quality of life (95% CI 15.5-22.9; P < .001), at an incremental cost of 29 604 Swiss francs (CHF) (95% CI 16 354-42 855; P < .001). The estimated ICER was CHF 158 612 per quality-adjusted life-year (QALY) gained within a 5-year time horizon. Assuming similar health effects and costs over 5 additional years changed the ICER to CHF 82 195 per QALY gained. Results were robust to the sensitivity analyses performed. CONCLUSIONS Our results show that PVI might be a cost-effective intervention within the Swiss healthcare context in a 10-year time horizon, but unlikely to be so at 5 years, if a willingness-to-pay threshold of CHF 100 000 per QALY gained is assumed. Given data availability, we find target trial designs are a valuable tool for assessing the cost-effectiveness of healthcare interventions outside of randomized controlled trial settings.

Published
2023

127. Arrhythmias and Clinical Outcomes in a Swiss Multicenter Cohort of Patients With Dextro-Transposition of the Great Arteries and Atrial Switch

Author

Nozica, Nikolas; https://orcid.org/0000-0001-9686-8928, Asatryan, Babken; https://orcid.org/0000-0002-0050-5717, Aur, Stefania, Clement, Judith Bouchardy; https://orcid.org/0000-0003-0149-288X, Schwerzmann, Markus; https://orcid.org/0000-0002-4006-8929, Guan, Fu; https://orcid.org/0000-0002-1832-4201, Pascale, Patrizio; https://orcid.org/0000-0001-7328-2481, Gass, Matthias; https://orcid.org/0000-0001-5875-1745, Duru, Firat; https://orcid.org/0000-0002-4748-0158, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Pruvot, Etienne; https://orcid.org/0000-0003-1386-9285, Wolber, Thomas; https://orcid.org/0000-0002-9143-5530, Roten, Laurent; https://orcid.org/0000-0002-0827-1329, Nozica, Nikolas; https://orcid.org/0000-0001-9686-8928, Asatryan, Babken; https://orcid.org/0000-0002-0050-5717, Aur, Stefania, Clement, Judith Bouchardy; https://orcid.org/0000-0003-0149-288X, Schwerzmann, Markus; https://orcid.org/0000-0002-4006-8929, Guan, Fu; https://orcid.org/0000-0002-1832-4201, Pascale, Patrizio; https://orcid.org/0000-0001-7328-2481, Gass, Matthias; https://orcid.org/0000-0001-5875-1745, Duru, Firat; https://orcid.org/0000-0002-4748-0158, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Pruvot, Etienne; https://orcid.org/0000-0003-1386-9285, Wolber, Thomas; https://orcid.org/0000-0002-9143-5530, and Roten, Laurent; https://orcid.org/0000-0002-0827-1329

Abstract

Background Data on the incidence of arrhythmias, associated cardiac interventions, and outcome in patients with dextro-transposition of the great arteries and atrial switch are scarce. Methods and Results In this multicenter analysis, we included adult patients with dextro-transposition of the great arteries and atrial switch regularly followed up at 3 Swiss tertiary care hospitals. The primary outcome was a composite of left ventricular assist device, heart transplantation, and death. The secondary outcome was occurrence of ventricular tachycardia, ventricular fibrillation, or sudden cardiac death. We identified 207 patients (34% women; median age at last follow-up, 35 years) with dextro-transposition of the great arteries and atrial switch. Arrhythmias occurred in 97 patients (47%) at a median age of 22 years. A pacemaker or an implantable cardioverter-defibrillator was implanted in 39 (19%) and 13 (6%) patients, respectively, and 33 (16%) patients underwent a total of 51 ablation procedures to target 60 intra-atrial re-entry tachycardias, 4 atrioventricular nodal re-entry tachycardias, and 1 atrial fibrillation. The primary outcome occurred in 21 patients (10%), and the secondary outcome occurred in 18 patients (9%); both were more common in patients with concomitant ventricular septum defect than in those without (hazard ratio [HR], 3.06 [95% CI, 1.29-7.27], P=0.011; and HR, 3.62 [95% CI, 1.43-9.18], P=0.007, respectively). Conclusions In patients with dextro-transposition of the great arteries and atrial switch reaching adulthood, arrhythmias occur in almost half of patients, and associated rhythm interventions are frequent. One-tenth of those patients do not survive until the age of 35 years free from left ventricular assist device or heart transplantation, and the outcome is worse in patients with concomitant ventricular septum defect.

Published
2023

128. Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort

Author

Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Serra-Burriel, Miquel, Foster-Wittassek, Fabienne, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Auricchio, Angelo, Beer, Jürg Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva, Bonati, Leo H, Conen, David, Felder, Stefan, Huber, Carola A, Kuehne, Michael, Mueller, Andreas, Oberle, Jolanda, Paladini, Rebecca E, Reichlin, Tobias, Rodondi, Nicolas, Springer, Anne, Stauber, Annina, Sticherling, Christian, Szucs, Thomas D, Osswald, Stefan, Schwenkglenks, Matthias, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Serra-Burriel, Miquel, Foster-Wittassek, Fabienne, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Auricchio, Angelo, Beer, Jürg Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva, Bonati, Leo H, Conen, David, Felder, Stefan, Huber, Carola A, Kuehne, Michael, Mueller, Andreas, Oberle, Jolanda, Paladini, Rebecca E, Reichlin, Tobias, Rodondi, Nicolas, Springer, Anne, Stauber, Annina, Sticherling, Christian, Szucs, Thomas D, Osswald, Stefan, and Schwenkglenks, Matthias

Abstract

Objective: Evidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study, we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories. Methods: Swiss-AF enrolled 2415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications. Results: A subpopulation of 1024 Swiss-AF patients with available claims data was followed up for a median (IQR) of 3.24 (1.09) years. Average yearly AF-adjudicated costs amounted to SFr5679 (€5163), remaining stable across the observation period. AF-adjudicated costs consisted mainly of inpatient and outpatient AF treatment costs (SFr4078; €3707), followed by costs of bleeding (SFr696; €633) and heart failure (SFr494; €449). Hierarchical analysis identified three patient clusters: cardiovascular (CV; N=253 with claims), isolated-symptomatic (IS; N=586) and severely morbid without cardiovascular disease (SM; N=185). The CV cluster and SM cluster depicted similarly high costs across all cost outcomes; IS patients accrued the lowest costs. Conclusion: Our results highlight three well-defined patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs. Keywords: Atrial Fibrillation; Health Care Economics and Organizations

Published
2023

131. Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0 h/1 h-algorithm for the early diagnosis of acute myocardial infarction

Author

Nestelberger, Thomas, Wildi, Karin, Boeddinghaus, Jasper, Twerenbold, Raphael, Reichlin, Tobias, Giménez, Maria Rubini, Puelacher, Christian, Jaeger, Cedric, Grimm, Karin, Sabti, Zaid, Hillinger, Petra, Kozhuharov, Nikola, du Fay de Lavallaz, Jeanne, Pinck, Florentina, Lopez, Beatriz, Salgado, Emilio, Miró, Òscar, Bingisser, Roland, Lohrmann, Jens, Osswald, Stefan, and Mueller, Christian

Published
2016
Full Text
View/download PDF

132. Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation

Author

Hennings, Elisa, Blum, Steffen, Aeschbacher, Stefanie, Coslovsky, Michael, Knecht, Sven, Eken, Ceylan, Lischer, Mirko, Paladini, Rebecca E, Krisai, Philipp, Reichlin, Tobias, Rodondi, Nicolas, Beer, Jürg H, Ammann, Peter, Conte, Giulio, De Perna, Maria Luisa, Kobza, Richard, Blum, Manuel R, Bossard, Matthias, Kastner, Peter, Ziegler, André, Müller, Christian, Bonati, Leo H, Pfister, Otmar, Zuern, Christine S, Conen, David, Kühne, Michael, and Osswald, Stefan

Subjects
360 Social problems & social services, 610 Medicine & health, Cardiology and Cardiovascular Medicine
Abstract

Background Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial‐specific biomarker BMP10 (bone morphogenetic protein 10) for death and MACE in patients with AF in comparison with NT‐proBNP (N‐terminal prohormone of B‐type natriuretic peptide). Methods and Results BMP10 and NT‐proBNP were measured in patients with AF enrolled in Swiss‐AF (Swiss Atrial Fibrillation Study), a prospective multicenter cohort study. A total of 2219 patients were included (median follow‐up 4.3 years [interquartile range 3.9, 5.1], mean age 73±9 years, 73% male). In multivariable Cox proportional hazard models, the adjusted hazard ratio (aHR) associated with 1 ng/mL increase of BMP10 was 1.60 (95% CI, 1.37–1.87) for all‐cause death, and 1.54 (95% CI, 1.35–1.76) for MACE. For all‐cause death, the concordance index was 0.783 (95% CI, 0.763–0.809) for BMP10, 0.784 (95% CI, 0.765–0.810) for NT‐proBNP, and 0.789 (95% CI, 0.771–0.815) for both biomarkers combined. For MACE, the concordance index was 0.732 (95% CI, 0.715–0.754) for BMP10, 0.747 (95% CI, 0.731–0.768) for NT‐proBNP, and 0.750 (95% CI, 0.734–0.771) for both biomarkers combined. When grouping patients according to NT‐proBNP categories (900 ng/L), higher aHRs were observed in patients with high BMP10 in the categories of low NT‐proBNP (all‐cause death aHR, 2.28 [95% CI, 1.15–4.52], MACE aHR, 1.88 [95% CI, 1.07–3.28]) and high NT‐proBNP (all‐cause death aHR, 1.61 [95% CI, 1.14–2.26], MACE aHR, 1.38 [95% CI, 1.07–1.80]). Conclusions BMP10 strongly predicted all‐cause death and MACE in patients with AF. BMP10 provided additional prognostic information in low‐ and high‐risk patients according to NT‐proBNP stratification. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02105844.

Published
2023

133. Hyperacute T Wave in the Early Diagnosis of Acute Myocardial Infarction

Author

Koechlin, Luca, Strebel, Ivo, Zimmermann, Tobias, Nestelberger, Thomas, Walter, Joan, Lopez-Ayala, Pedro, Boeddinghaus, Jasper, Shrestha, Samyut, Arslani, Ketina, Stefanelli, Sabrina, Reuthebuch, Benedikt, Wussler, Desiree, Ratmann, Paul David, Christ, Michael, Badertscher, Patrick, Wildi, Karin, Giménez, Maria Rubini, Gualandro, Danielle Menosi, Miró, Òscar, Fuenzalida, Carolina, Martín-Sánchez, F Javier, Kawecki, Damian, Bürgler, Franz, Keller, Dagmar I, Abächerli, Roger, Reuthebuch, Oliver, Eckstein, Friedrich S, Twerenbold, Raphael, Reichlin, Tobias, Mueller, Christian, APACE Investigators, and University of Zurich

Subjects
540 Chemistry, 610 Medicine & health, 10038 Institute of Clinical Chemistry
Published
2023

137. Validation of a clinical model for predicting left versus right ventricular outflow tract origin of idiopathic ventricular arrhythmias.

Author

Bourquin, Luc, Küffer, Thomas, Asatryan, Babken, Badertscher, Patrick, Baldinger, Samuel H., Knecht, Sven, Seiler, Jens, Spies, Florian, Servatius, Helge, Kühne, Michael, Noti, Fabian, Osswald, Stefan, Haeberlin, Andreas, Tanner, Hildegard, Roten, Laurent, Reichlin, Tobias, and Sticherling, Christian

Subjects
ARRHYTHMIA treatment, HYPERTENSION, AGE distribution, RETROSPECTIVE studies, CATHETER ablation, VENTRICULAR tachycardia, RISK assessment, SEX distribution, VENTRICULAR arrhythmia, THEORY, DESCRIPTIVE statistics, ELECTROCARDIOGRAPHY, ARRHYTHMIA, PREDICTION models, SENSITIVITY & specificity (Statistics), LONGITUDINAL method, ALGORITHMS, DISEASE risk factors
Abstract

Background: Prediction of the chamber of origin in patients with outflow tract ventricular arrhythmias (OTVA) remains challenging. A clinical risk score based on age, sex and presence of hypertension was associated with a left ventricular outflow tract (LVOT) origin. We aimed to validate this clinical score to predict an LVOT origin in patients with OTVA. Methods: In a two‐center observational cohort study, unselected patients undergoing catheter ablation (CA) for OTVA were enrolled. All procedures were performed using an electroanatomical mapping system. Successful ablation was defined as a ≥80% reduction of the initial overall PVC burden after 3 months of follow‐up. Patients with unsuccessful ablation were excluded from this analysis. Results: We included 187 consecutive patients with successful CA of idiopathic OTVA. Mean age was 52 ± 15 years, 102 patients (55%) were female, and 74 (40%) suffered from hypertension. A LVOT origin was found in 64 patients (34%). A score incorporating age, sex and presence of hypertension reached 73% sensitivity and 67% specificity for a low (0–1) and high (2–3) score, to predict an LVOT origin. The combination of one ECG algorithm (V2S/V3R‐index) with the clinical score resulted in a sensitivity and specificity of 81% and 70% for PVCs with R/S transition at V3. Conclusion: The published clinical score yielded a lower sensitivity and specificity in our cohort. However, for PVCs with R/S transition at V3, the combination with an existing ECG algorithm can improve the predictability of LVOT origin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

138. Recurrences of ventricular tachycardia after stereotactic arrhythmia radioablation arise outside the treated volume: analysis of the Swiss cohort.

Author

Siklody, Claudia Herrera, Schiappacasse, Luis, Jumeau, Raphaël, Reichlin, Tobias, Saguner, Ardan M, Andratschke, Nicolaus, Elicin, Olgun, Schreiner, Frederic, Kovacs, Boldizsar, Mayinger, Michael, Huber, Adrian, Verhoeff, Joost J C, Pascale, Patrizio, Muñoz, Jorge Solana, Luca, Adrian, Domenichini, Giulia, Moeckli, Raphael, Bourhis, Jean, Ozsahin, Esat M, and Pruvot, Etienne

Abstract

Aims Stereotactic arrhythmia radioablation (STAR) has been recently introduced for the management of therapy-refractory ventricular tachycardia (VT). VT recurrences have been reported after STAR but the mechanisms remain largely unknown. We analysed recurrences in our patients after STAR. Methods and results From 09.2017 to 01.2020, 20 patients (68 ± 8 y, LVEF 37 ± 15%) suffering from refractory VT were enrolled, 16/20 with a history of at least one electrical storm. Before STAR, an invasive electroanatomical mapping (Carto3) of the VT substrate was performed. A mean dose of 23 ± 2 Gy was delivered to the planning target volume (PTV). The median ablation volume was 26 mL (range 14–115) and involved the interventricular septum in 75% of patients. During the first 6 months after STAR, VT burden decreased by 92% (median value, from 108 to 10 VT/semester). After a median follow-up of 25 months, 12/20 (60%) developed a recurrence and underwent a redo ablation. VT recurrence was located in the proximity of the treated substrate in nine cases, remote from the PTV in three cases and involved a larger substrate over ≥3 LV segments in two cases. No recurrences occurred inside the PTV. Voltage measurements showed a significant decrease in both bipolar and unipolar signal amplitude after STAR. Conclusion STAR is a new tool available for the treatment of VT, allowing for a significant reduction of VT burden. VT recurrences are common during follow-up, but no recurrences were observed inside the PTV. Local efficacy was supported by a significant decrease in both bipolar and unipolar signal amplitude. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

140. Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation

Author

Luciani, Marco, primary, Müller, Daniel, additional, Vanetta, Chiara, additional, Diteepeng, Thamonwan, additional, von Eckardstein, Arnold, additional, Aeschbacher, Stefanie, additional, Rodondi, Nicolas, additional, Moschovitis, Giorgio, additional, Reichlin, Tobias, additional, Sinnecker, Tim, additional, Wuerfel, Jens, additional, Bonati, Leo H, additional, Saeedi Saravi, Seyed Soheil, additional, Chocano-Bedoya, Patricia, additional, Coslovsky, Michael, additional, Camici, Giovanni G, additional, Lüscher, Thomas F, additional, Kuehne, Michael, additional, Osswald, Stefan, additional, Conen, David, additional, and Beer, Jürg Hans, additional

Published
2023
Full Text
View/download PDF

141. Early rule-out and rule-in of myocardial infarction using sensitive cardiac Troponin I

Author

Druey, Sophie, Wildi, Karin, Twerenbold, Raphael, Jaeger, Cédric, Reichlin, Tobias, Haaf, Philip, Rubini Gimenez, Maria, Puelacher, Christian, Wagener, Max, Radosavac, Milos, Honegger, Ursina, Schumacher, Carmela, Delfine, Valentina, Kreutzinger, Philip, Herrmann, Thomas, Moreno Weidmann, Zoraida, Krivoshei, Lian, Freese, Michael, Stelzig, Claudia, Isenschmid, Cyril, Bassetti, Stefano, Rentsch, Katharina, Osswald, Stefan, and Mueller, Christian

Published
2015
Full Text
View/download PDF

142. One-hour Rule-in and Rule-out of Acute Myocardial Infarction Using High-sensitivity Cardiac Troponin I

Author

Rubini Gimenez, Maria, Twerenbold, Raphael, Jaeger, Cedric, Schindler, Christian, Puelacher, Christian, Wildi, Karin, Reichlin, Tobias, Haaf, Philip, Merk, Salome, Honegger, Ursina, Wagener, Max, Druey, Sophie, Schumacher, Carmela, Krivoshei, Lian, Hillinger, Petra, Herrmann, Thomas, Campodarve, Isabel, Rentsch, Katharina, Bassetti, Stefano, Osswald, Stefan, and Mueller, Christian

Published
2015
Full Text
View/download PDF

143. Incremental value of copeptin to highly sensitive cardiac Troponin I for rapid rule-out of myocardial infarction

Author

Wildi, Karin, Zellweger, Christa, Twerenbold, Raphael, Jaeger, Cedric, Reichlin, Tobias, Haaf, Philip, Faoro, Jonathan, Giménez, Maria Rubini, Fischer, Andreas, Nelles, Berit, Druey, Sophie, Krivoshei, Lian, Hillinger, Petra, Puelacher, Christian, Herrmann, Thomas, Campodarve, Isabel, Rentsch, Katharina, Steuer, Stephan, Osswald, Stefan, and Mueller, Christian

Published
2015
Full Text
View/download PDF

144. Incremental Value of a Single High-sensitivity Cardiac Troponin I Measurement to Rule Out Myocardial Ischemia

Author

Tanglay, Yunus, Twerenbold, Raphael, Lee, Gino, Wagener, Max, Honegger, Ursina, Puelacher, Christian, Reichlin, Tobias, Sou, Seoung Mann, Druey, Sophie, Hochgruber, Thomas, Zürcher, Stephan, Radosavac, Milos, Kreutzinger, Philipp, Pretre, Gilles, Stallone, Fabio, Hillinger, Petra, Jaeger, Cedric, Rubini Gimenez, Maria, Freese, Michael, Wild, Damian, Rentsch, Katharina, Osswald, Stefan, Zellweger, Michael J., and Mueller, Christian

Published
2015
Full Text
View/download PDF

145. Accelerated diagnostic protocol using high-sensitivity cardiac troponin T in acute chest pain patients

Author

Meller, Bernadette, Cullen, Louise, Parsonage, William A., Greenslade, Jaimi H., Aldous, Sally, Reichlin, Tobias, Wildi, Karin, Twerenbold, Raphael, Jaeger, Cedric, Hillinger, Petra, Haaf, Philip, Puelacher, Christian, Kern, Vera, Rentsch, Katharina, Stallone, Fabio, Rubini Gimenez, Maria, Ballarino, Paola, Bassetti, Stefano, Walukiewicz, Astrid, Troughton, Richard, Pemberton, Christopher J., Richards, A. Mark, Chu, Kevin, Reid, Christopher M., Than, Martin, and Mueller, Christian

Published
2015
Full Text
View/download PDF

148. Association of Chronic Covert Cerebral Infarctions and White Matter Hyperintensities With Atrial Fibrillation Detection on Post‐Stroke Cardiac Rhythm Monitoring: A Cohort Study

Author

Amberger, Ulfrid, primary, Lippert, Julian, additional, Mujanovic, Adnan, additional, Beyeler, Morin, additional, Siepen, Bernhard, additional, Vynckier, Jan, additional, Scutelnic, Adrian, additional, Goeldlin, Martina, additional, Seiffge, David, additional, Jung, Simon, additional, Gralla, Jan, additional, Arnold, Marcel, additional, Kaesmacher, Johannes, additional, Reichlin, Tobias, additional, Tanner, Hildegard, additional, Fischer, Urs, additional, Roten, Laurent, additional, and Meinel, Thomas Raphael, additional

Published
2022
Full Text
View/download PDF

149. Pulsed-field ablation for the treatment of left atrial reentry tachycardia

Author

Kueffer, Thomas, primary, Seiler, Jens, additional, Madaffari, Antonio, additional, Mühl, Aline, additional, Asatryan, Babken, additional, Stettler, Robin, additional, Haeberlin, Andreas, additional, Noti, Fabian, additional, Servatius, Helge, additional, Tanner, Hildegard, additional, Baldinger, Samuel H., additional, Reichlin, Tobias, additional, and Roten, Laurent, additional

Published
2022
Full Text
View/download PDF

150. Conduction System Pacing Today and Tomorrow

Author

Haeberlin, Andreas, primary, Canello, Siro, additional, Kummer, Andreas, additional, Seiler, Jens, additional, Baldinger, Samuel H., additional, Madaffari, Antonio, additional, Thalmann, Gregor, additional, Ryser, Adrian, additional, Gräni, Christoph, additional, Tanner, Hildegard, additional, Roten, Laurent, additional, Reichlin, Tobias, additional, and Noti, Fabian, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results